| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_af988c6711e6272dc252709fd2f8087e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cf32b60391b469c41e86c353437f5751
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5cca45842e7409a94a1f599245519676
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d50c67a51644a0d20074b8fd714cb5ec
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9f3f626277122677922565102a2d3813
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2f700c852c397139f64a77a20472d356 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-916
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-42
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57426
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-16 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 |
| filingDate |
2009-11-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_963722621297f0a02a5e03b27feed621
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_949ebebc44301fc7f3fd637b948ba93d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_67052d641a79352bfe6da44b434727c8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a13e2b4dd606004a06f6f7cf51f61838
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_aca52a5cd619c4970130b3fd9011bbb3 |
| publicationDate |
2010-05-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2010054045-A1 |
| titleOfInvention |
Method for optimizing the treatment of chronic myeloid leukemia with abl tyrosine kinase inhibitors |
| abstract |
The present invention relates to a method for evaluating patients to help optimizing the treatment of chronic myeloid leukemia (CML) in a human patient population. Specifically, present invention relates to SHP1 and/or SHP2 as a biomarker for CML patients. |
| priorityDate |
2008-11-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |